These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 22192852)

  • 1. Correlation of antinuclear antibody and anti-double-stranded DNA antibody with clinical response to infliximab in patients with rheumatoid arthritis: a retrospective clinical study.
    Yukawa N; Fujii T; Kondo-Ishikawa S; Yoshifuji H; Kawabata D; Nojima T; Ohmura K; Usui T; Mimori T
    Arthritis Res Ther; 2011; 13(6):R213. PubMed ID: 22192852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Presence of anti-nuclear antibodies is a risk factor for the appearance of anti-drug antibodies during infliximab or adalimumab therapy in patients with rheumatoid arthritis.
    Mori A; Saito T; Takahashi M; Shibata M; Tsuji G; Hatachi S; Takahashi S; Kumagai S
    PLoS One; 2020; 15(12):e0243729. PubMed ID: 33315881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of ANA specificity using multiplexed fluorescent microsphere immunoassay in patients with ANA positivity at high titres after infliximab treatment: preliminary results.
    Caramaschi P; Ruzzenente O; Pieropan S; Volpe A; Carletto A; Bambara LM; Biasi D
    Rheumatol Int; 2007 May; 27(7):649-54. PubMed ID: 17136355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy.
    De Rycke L; Kruithof E; Van Damme N; Hoffman IE; Van den Bossche N; Van den Bosch F; Veys EM; De Keyser F
    Arthritis Rheum; 2003 Apr; 48(4):1015-23. PubMed ID: 12687543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis.
    Bruns A; Nicaise-Roland P; Hayem G; Palazzo E; Dieudé P; Grootenboer-Mignot S; Chollet-Martin S; Meyer O
    Joint Bone Spine; 2009 May; 76(3):248-53. PubMed ID: 19208451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-TNFalpha therapy in rheumatoid arthritis and autoimmunity.
    Caramaschi P; Biasi D; Colombatti M; Pieropan S; Martinelli N; Carletto A; Volpe A; Pacor LM; Bambara LM
    Rheumatol Int; 2006 Jan; 26(3):209-14. PubMed ID: 15627197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers.
    Gonnet-Gracia C; Barnetche T; Richez C; Blanco P; Dehais J; Schaeverbeke T
    Clin Exp Rheumatol; 2008; 26(3):401-7. PubMed ID: 18578960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-nucleosome antibodies as prediction factor of development of autoantibodies during therapy with three different TNFalpha blocking agents in rheumatoid arthritis.
    Benucci M; Saviola G; Baiardi P; Cammelli E; Manfredi M
    Clin Rheumatol; 2008 Jan; 27(1):91-5. PubMed ID: 17929076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antinuclear, anti-dsDNA and anti-ENA antibodies in patients affected with rheumatoid arthritis or ankylosing spondylitis during treatment with infliximab].
    Hoxha A; Ruffatti A; Grypiotis P; Podswiadek M; Botsios C; Fiocco U; Punzi L; Todesco S
    Reumatismo; 2006; 58(2):121-6. PubMed ID: 16829990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-nuclear antibody development is associated with poor treatment response to biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.
    Ishikawa Y; Hashimoto M; Ito H; Tanaka M; Yukawa N; Fujii T; Yamamoto W; Mimori T; Terao C
    Semin Arthritis Rheum; 2019 Oct; 49(2):204-210. PubMed ID: 30803720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of anti-Ro/SSA antibody with response to biologics in patients with rheumatoid arthritis.
    Hagiwara S; Tsuboi H; Honda F; Takahashi H; Kurata I; Ohyama A; Yagishita M; Abe S; Kurashima Y; Kaneko S; Kawaguchi H; Takahashi H; Ebe H; Yokosawa M; Asashima H; Hirota T; Umeda N; Kondo Y; Matsumoto I; Sumida T
    Mod Rheumatol; 2016 Nov; 26(6):857-862. PubMed ID: 26873159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Association of short-term efficacy for infliximab in rheumatoid arthritis with plasma concentration and anti-drug antibody].
    Song M; Li F; Xie X; Chen J; Tang M; Tian J; Du J; Ge Y; Li S; Xu S
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Sep; 43(9):982-986. PubMed ID: 30333289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Anti-TNFalpha treatment in patients with rheumatoid arthritis and anti-Ro/SSA antibodies].
    Cavazzana I; Franceschini F; Danieli E; Frassi M; Vianelli M; Gorla R; Airò P; Cattaneo R
    Reumatismo; 2005 Dec; 57(4):267-72. PubMed ID: 16380754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with longterm infliximab therapy.
    Comby E; Tanaff P; Mariotte D; Costentin-Pignol V; Marcelli C; Ballet JJ
    J Rheumatol; 2006 Jan; 33(1):24-30. PubMed ID: 16395746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials.
    Charles PJ; Smeenk RJ; De Jong J; Feldmann M; Maini RN
    Arthritis Rheum; 2000 Nov; 43(11):2383-90. PubMed ID: 11083258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.
    De Rycke L; Baeten D; Kruithof E; Van den Bosch F; Veys EM; De Keyser F
    Arthritis Rheum; 2005 Jul; 52(7):2192-201. PubMed ID: 15986349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoantibodies profile of rheumatoid arthritis patients during treatment with infliximab.
    Elkayam O; Burke M; Vardinon N; Zakut V; Yitzhak RB; Paran D; Levartovsky D; Litinsky I; Caspi D
    Autoimmunity; 2005 Mar; 38(2):155-60. PubMed ID: 16040336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment.
    Caramaschi P; Biasi D; Tonolli E; Pieropan S; Martinelli N; Carletto A; Volpe A; Bambara LM
    Rheumatol Int; 2005 Nov; 26(1):58-62. PubMed ID: 15726373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of three anti-TNFalpha biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patients.
    Bacquet-Deschryver H; Jouen F; Quillard M; Ménard JF; Goëb V; Lequerré T; Mejjad O; Daragon A; Tron F; Le Loët X; Vittecoq O
    J Clin Immunol; 2008 Sep; 28(5):445-55. PubMed ID: 18587633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antinuclear Antibodies and Lupus-like Manifestations in Rheumatoid Arthritis and Ankylosing Spondylitis Patients at 4 Months' Follow-up After Treatment with Infliximab and Etanercept.
    Aghdashi MA; Khadir M; Dinparasti-Saleh R
    Curr Rheumatol Rev; 2020; 16(1):61-66. PubMed ID: 31057111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.